This site is intended for U.S.
healthcare professionals.

Jump to section:

Copay

ServierONE connects your eligible patients to the right support programs and services that may help them pay for their TIBSOVO treatment.

The TIBSOVO Copay Program can help lower out-of-pocket costs for commercially insured patients

Enroll your patients

Eligible commercially insured patients may pay as little as $0 per prescription for TIBSOVO through the Copay Program.

Who is eligible?*

  • Patients who reside in the U.S., U.S. territories, or Puerto Rico
  • Patients who are commercially or privately insured and paying a portion of the cost

*Not valid for patients whose prescription claims are reimbursed in whole or in part by any state or federal government program, including Medicaid, Medicare, Veterans Affairs (VA), Department of Defense (DOD), and TRICARE.

ServierONE Logo.

Patient support services

ServierONE® connects your eligible patients to the right support programs and services that may help them pay for their TIBSOVO treatment.

Support For Your Patient Every Step of the Way

We offer:

  • Support with insurance coverage and reimbursement
  • Financial assistance to help patients pay for TIBSOVO
  • Tools and resources to navigate insurance
  • Access to a one-on-one Patient Experience Manager

To receive more information

VISIT ServierONE.com
OR
CALL 1-800-813-5905 Monday‐Friday, 8 AM to 8 PM ET to contact a
Patient Services representative directly.

Register online for the Commercial Copay Program at ServierONE-copay.com.

Ordering and distribution network

National Drug Code (NDC)

NDCs 10-digit code: 72694-617-60
11-digit code: 72694-0617-60
Dosage strength 250 mg/tablet
Description 250-mg tablet: Blue oval-shaped film-coated tablet debossed “IVO” on one side and “250” on the other side

The red zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.

TIBSOVO® (ivosidenib tablets) bottle with two pills.

Tablet not to scale

Product information

How TIBSOVO is supplied: 250-mg tablets, supplied in 60-count bottles (30-day supply) with a desiccant canister

Storage: Store at 20 to 25 ºC (68 to 77 ºF)

Distribution network for TIBSOVO

TIBSOVO is only available through our specialty distributors and network specialty pharmacies.

Specialty distributors

TIBSOVO is available through specialty distributors for shipment directly to office- or hospital-based pharmacies.

McKesson Specialty Health

Cardinal Health Specialty Pharmaceutical Distribution (US)

Oncology Supply

Network specialty pharmacies

TIBSOVO ships directly from the specialty pharmacy to your patient’s home or preferred location.

Network Specialty Pharmacies with Direct-to-Home Delivery

See FAQs for TIBSOVO
 

Indication

TIBSOVO is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

QTc Interval Prolongation: Patients treated with TIBSOVO can develop QT (QTc) prolongation and ventricular arrhythmias. Concomitant use of TIBSOVO with drugs known to prolong the QTc interval (e.g., anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5‑HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or in those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary.

Interrupt TIBSOVO if QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVO if QTc increases to greater than 500 msec. Permanently discontinue TIBSOVO in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.

Guillain-Barré Syndrome: Guillain-Barré syndrome can develop in patients treated with TIBSOVO. Monitor patients taking TIBSOVO for onset of new signs or symptoms of motor and/or sensory neuropathy such as unilateral or bilateral weakness, sensory alterations, paresthesias, or difficulty breathing. Permanently discontinue TIBSOVO in patients who are diagnosed with Guillain-Barré syndrome.

ADVERSE REACTIONS

The most common adverse reactions (≥15%) in patients with cholangiocarcinoma were fatigue, nausea, abdominal pain, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, and rash. The most common laboratory abnormalities (≥10%) were hemoglobin decreased, aspartate aminotransferase increased, and bilirubin increased.

DRUG INTERACTIONS

Strong or Moderate CYP3A4 Inhibitors: Reduce TIBSOVO dose with strong CYP3A4 inhibitors. Monitor patients for increased risk of QTc interval prolongation.

Strong CYP3A4 Inducers: Avoid concomitant use with TIBSOVO.

Sensitive CYP3A4 Substrates: Avoid concomitant use with TIBSOVO.

QTc Prolonging Drugs: Avoid concomitant use with TIBSOVO. If co-administration is unavoidable, monitor patients for increased risk of QTc interval prolongation.

LACTATION

Advise women not to breastfeed.

Please see Full Prescribing Information.

 

Indication & Important Safety Information

INDICATION

TIBSOVO is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

QTc Interval Prolongation: Patients treated with TIBSOVO can develop QT (QTc) prolongation and ventricular arrhythmias. Concomitant use of TIBSOVO with drugs known to prolong the QTc interval (eg, anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or in those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Interrupt TIBSOVO if QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVO if QTc increases to greater than 500 msec. Permanently discontinue TIBSOVO in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.